The combination of anti-PD-1 (cemiplimab) and anti-CD38 (isatuximab) monoclonal antibodies resulted in the activation of peripheral T cells in patients with mCRPC and a median reduction in CD38+ tumor-infiltrating immune cells, from 40% to 3% (NCT03367819) [114]. This evidence concerns the gene CD38 and neoplasm.